Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01688011 · ClinicalTrials.gov registry record
Connect® Myeloid Disease Registry
A clinical trial, sponsored by Celgene.
- Terminated
- Registry status
- 2,013
- Enrollment target
NCT01688011 is a clinical trial that was terminated before completion, run by Celgene. The registered enrollment target is 2,013 participants.
The verdict
NCT01688011 was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- 2,013 participants
- Enrollment target
Study Summary
The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification which may or may not be predictive of therapy and clinical outcomes.
Interventions
- DRUG Luspatercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,013 participants |
| Start Date | 2013-12-12 |
| Est. Completion | 2024-10-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01688011
The ClinicalTrials.gov registry entry for NCT01688011 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 2,013 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Luspatercept is the first listed.
NCT01688011 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01688011 about?
NCT01688011 is a clinical study titled "Connect® Myeloid Disease Registry". The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular marke...
What is the current status of trial NCT01688011?
This trial is currently terminated. The enrollment target is 2,013 participants. The study started on 2013-12-12. Estimated completion is 2024-10-18.
What interventions are being tested in trial NCT01688011?
The interventions under investigation include: Luspatercept (DRUG).
Who is sponsoring clinical trial NCT01688011?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.